Literature DB >> 21170085

Cyclin-dependent kinase 1 expression is inhibited by p16(INK4a) at the post-transcriptional level through the microRNA pathway.

W W Chien1, C Domenech, R Catallo, T Kaddar, J-P Magaud, G Salles, M Ffrench.   

Abstract

The p16(INK4a) protein regulates cell cycle progression mainly by inhibiting the activity of G1-phase cyclin-dependent kinases (CDKs) 4 and 6, the subsequent retinoblastoma protein (pRb) phosphorylation and E2F transcription factor release. The p16(INK4a) protein can also repress the activity of other transcription factors, such as c-myc, nuclear factor-kappaB and c-Jun/AP1. Here, we report that, in two p16(-/-), pRb(WT) and p53(WT) cell lines (MCF7 and U87), p16(INK4a) overexpression induces a dramatic decrease in CDK1 protein expression. In response to p16(INK4a), the decreased rate of CDK1 protein synthesis, its unchanged protein half-life, unreduced CDK1 mRNA steady-state levels and mRNA half-life allow us to hypothesize that p16(INK4a) could regulate CDK1 expression at the post-transcriptional level. This CDK1 downregulation is mediated by the 3'-untranslated region (3'UTR) of CDK1 mRNA as shown by translational inhibition in luciferase assays and is associated with a modified expression balance of microRNAs (miRNAs) that potentially regulate CDK1, analyzed by TaqMan Human microRNA Array. The p16(INK4a)-induced expression of two miRNAs (miR-410 and miR-650 chosen as an example) in MCF7 cells is confirmed by individual reverse transcription-qPCR. Furthermore, we show the interaction of miR-410 or miR-650 with CDK1-3'UTR by luciferase assays. Endogenous CDK1 expression decreases upon both miRNA overexpression and increases with their simultaneous inhibition. The induction of miR-410, but not miR-650 could be related to the pRb/E2F pathway. These results demonstrate the post-transcriptional inhibition of CDK1 by p16(INK4a). We suggest that p16(INK4a) may regulate gene expression by modifying the functional equilibrium of transcription factors and consequently the expression balance of miRNAs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21170085     DOI: 10.1038/onc.2010.570

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

Review 1.  microRNAs in cancer cell response to ionizing radiation.

Authors:  Jennifer R Czochor; Peter M Glazer
Journal:  Antioxid Redox Signal       Date:  2014-02-04       Impact factor: 8.401

2.  miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA.

Authors:  Francesca Maria Orlandella; Raffaela Mariarosaria Mariniello; Paola Lucia Chiara Iervolino; Esther Imperlini; Annalisa Mandola; Anna Verde; Anna Elisa De Stefano; Katia Pane; Monica Franzese; Silvia Esposito; Fulvio Basolo; Stefania Orrù; Giuliana Salvatore
Journal:  Endocrine       Date:  2019-03-29       Impact factor: 3.633

3.  NSun2 Promotes Cell Growth via Elevating Cyclin-Dependent Kinase 1 Translation.

Authors:  Junyue Xing; Jie Yi; Xiaoyu Cai; Hao Tang; Zhenyun Liu; Xiaotian Zhang; Jennifer L Martindale; Xiaoling Yang; Bin Jiang; Myriam Gorospe; Wengong Wang
Journal:  Mol Cell Biol       Date:  2015-09-21       Impact factor: 4.272

4.  Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.

Authors:  Henriett Butz; Kinga Németh; Dóra Czenke; István Likó; Sándor Czirják; Vladimir Zivkovic; Kornélia Baghy; Márta Korbonits; Ilona Kovalszky; Péter Igaz; Károly Rácz; Attila Patócs
Journal:  Pathol Oncol Res       Date:  2016-12-21       Impact factor: 3.201

5.  Essential role of microRNA-650 in the regulation of B-cell CLL/lymphoma 11B gene expression following transplantation: A novel mechanism behind the acute rejection of renal allografts.

Authors:  Peng Jin; Hongxi Chen; Jinliang Xie; Cheng Zhou; Xiangrong Zhu
Journal:  Int J Mol Med       Date:  2017-10-17       Impact factor: 4.101

6.  CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid.

Authors:  Tatsuya Yunoki; Tetsushi Hirano; Yoshiaki Tabuchi; Yukihiro Furusawa; Misako Torigoe; Takahiko Nakajima; Johji Imura; Atsushi Hayashi
Journal:  Int Ophthalmol       Date:  2019-09-30       Impact factor: 2.031

Review 7.  The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis.

Authors:  Leonidas Benetatos; Eleftheria Hatzimichael; Eric Londin; George Vartholomatos; Phillipe Loher; Isidore Rigoutsos; Evangelos Briasoulis
Journal:  Cell Mol Life Sci       Date:  2012-07-24       Impact factor: 9.261

Review 8.  Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.

Authors:  Satyanarayana Rachagani; Muzafar A Macha; Nicholas Heimann; Parthasarathy Seshacharyulu; Dhanya Haridas; Seema Chugh; Surinder K Batra
Journal:  Adv Drug Deliv Rev       Date:  2014-10-23       Impact factor: 15.470

Review 9.  Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy.

Authors:  Lin-hui Liang; Xiang-huo He
Journal:  Acta Pharmacol Sin       Date:  2011-09-12       Impact factor: 6.150

Review 10.  Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer.

Authors:  Siuwah Tang; Jillian Bonaroti; Sebnem Unlu; Xiaoyan Liang; Daolin Tang; Herbert J Zeh; Michael T Lotze
Journal:  Pancreas       Date:  2013-07       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.